Know Cancer

or
forgot password

A Phase II, Open-Label, Non-Randomized, Multicenter, Single Agent Study of Intravenous SDX-102 for the Treatment of Patients With MTAP-Deficient Cancer


Phase 2
13 Years
N/A
Not Enrolling
Both
Lung Cancer, Malignant Mesothelioma, Pancreatic Cancer, Sarcoma

Thank you

Trial Information

A Phase II, Open-Label, Non-Randomized, Multicenter, Single Agent Study of Intravenous SDX-102 for the Treatment of Patients With MTAP-Deficient Cancer


OBJECTIVES:

- Determine the response rates in patients with methylthioadenosine phosphorylase
(MTAP)-deficient cancer when treated with alanosine.

- Determine the time to response and duration of response in patients treated with this
drug.

- Determine the progression-free survival of patients treated with this drug.

- Determine the pharmacodynamic activity of this drug in these patients, based on special
imaging to measure tumor adenosine triphosphate depletion.

- Determine the pharmacokinetic activity of this drug in these patients.

- Determine the safety and tolerability of this drug in these patients.

OUTLINE: This is a nonrandomized, open-label, multicenter study.

Patients receive alanosine IV continuously on days 1-5. Treatment repeats every 21 days for
up to 9 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed at 28 days.

PROJECTED ACCRUAL: A total of 50-145 patients (10-29 per tumor type) will be accrued for
this study.

Inclusion Criteria


DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed malignancy of any of the following types:

- Soft-tissue sarcoma

- High grade

- Chemotherapy naïve or progressive or metastatic after no more than 2 prior
cytotoxic treatment regimens (not including adjuvant therapy)

- Sarcoma of the bone (including osteosarcoma* and chondrosarcoma)

- High grade

- Progressive or recurrent after no more than 2 prior cytotoxic treatment
regimens

- No newly diagnosed or chemotherapy naïve disease NOTE: *Prior treatment
with cisplatin and doxorubicin required

- Mesothelioma

- Unresectable

- Chemotherapy naïve or progressive after no more than 1 prior cytotoxic
chemotherapy regimen

- Not amenable to curative treatment with surgery

- Evidence of gross unresectability includes, but is not limited to,
direct extension into the chest wall, mediastinal or hilar
lymphadenopathy, pulmonary or cardiac function that is inadequate to
tolerate resection, and sarcomatoid or mixed histology

- Non-small cell lung cancer

- Stage III with malignant pleural or pericardial effusion, stage IV, or
progressive after no more than 2 prior cytotoxic chemotherapy regimens

- No newly diagnosed or chemotherapy naïve disease

- Pancreatic cancer

- Stage IV adenocarcinoma after no more than 1 prior cytotoxic treatment
regimen

- No newly diagnosed or chemotherapy naïve disease

- No Ewing's sarcoma of the soft tissue or bone

- Documented absence of methylthioadenosine phosphorylase on fixed tumor specimens

- Measurable disease

- For all tumor types, at least 1 lesion measurable by MRI or CT scan

- Chest x-ray allowed only for clearly defined lesions surrounded by aerated lung

- Soft tissue component of bone disease considered measurable provided it can be
measured by MRI or CT scan

- Must be outside of a previously irradiated area

- No uncontrolled CNS metastases of primary tumor under study

- Patients with brain metastases are eligible only if the brain metastases have
been treated with prior radiotherapy and/or surgery, are neurologically stable
with no progressing symptoms, and are off steroids and anticonvulsants

PATIENT CHARACTERISTICS:

Age

- 18 and over (13 and over for osteosarcoma only)

Performance status

- WHO 0-2

Life expectancy

- At least 3 months

Hematopoietic

- Absolute granulocyte count at least 1,500/mm^3

- Platelet count at least 100,000/mm^3

Hepatic

- Bilirubin no greater than 1.5 times upper limit of normal (ULN)

- Alkaline phosphatase no greater than 2.5 times ULN

- AST and ALT no greater than 2.5 times ULN (5 times ULN if liver metastases are
present)

Renal

- Creatinine no greater than 1.5 times ULN

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective barrier contraception during and for 4 weeks
after study treatment

- No premalignant bony lesions (e.g., Paget's disease)

- No other concurrent active malignancy except completely excised nonmelanoma skin
cancer or carcinoma in situ of the cervix or bladder

- No serious infection

- No medical or psychiatric condition that would preclude the achievement of the study
objectives

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Not specified

Chemotherapy

- See Disease Characteristics

- More than 42 days since prior nitrosoureas or mitomycin

Endocrine therapy

- See Disease Characteristics

Radiotherapy

- See Disease Characteristics

- At least 28 days since prior brain radiotherapy

- More than 28 days since prior radiotherapy to more than 50% of the bone marrow

Surgery

- See Disease Characteristics

- At least 28 days since prior thoracic or other major surgery

Other

- Recovered from prior therapy

- More than 28 days since prior cytotoxic agents

- More than 28 days since prior anticancer investigational agents

- No other concurrent anti-tumor treatment

Type of Study:

Interventional

Study Design:

Masking: Open Label, Primary Purpose: Treatment

Principal Investigator

Paul A. Meyers, MD

Investigator Role:

Study Chair

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center

Authority:

United States: Federal Government

Study ID:

SALMEDIX-SDX-102-01

NCT ID:

NCT00062283

Start Date:

March 2003

Completion Date:

December 2009

Related Keywords:

  • Lung Cancer
  • Malignant Mesothelioma
  • Pancreatic Cancer
  • Sarcoma
  • advanced malignant mesothelioma
  • recurrent malignant mesothelioma
  • metastatic osteosarcoma
  • recurrent osteosarcoma
  • recurrent adult soft tissue sarcoma
  • stage IV adult soft tissue sarcoma
  • chondrosarcoma
  • recurrent non-small cell lung cancer
  • stage IIIB non-small cell lung cancer
  • stage IV non-small cell lung cancer
  • adenocarcinoma of the pancreas
  • recurrent pancreatic cancer
  • stage III adult soft tissue sarcoma
  • stage II adult soft tissue sarcoma
  • stage IV pancreatic cancer
  • Lung Neoplasms
  • Mesothelioma
  • Pancreatic Neoplasms
  • Sarcoma

Name

Location

Memorial Sloan-Kettering Cancer CenterNew York, New York  10021
University of Chicago Cancer Research CenterChicago, Illinois  60637
University of Alabama at Birmingham Comprehensive Cancer CenterBirmingham, Alabama  35294-3300
Vanderbilt-Ingram Cancer Center at Vanderbilt Medical CenterNashville, Tennessee  37232-2516
Arizona Cancer Center at University of Arizona Health Sciences CenterTucson, Arizona  85724
St. Vincent's Comprehensive Cancer Center - ManhattanNew York, New York  10011
Cedars-Sinai Comprehensive Cancer Center at Cedars-Sinai Medical CenterLos Angeles, California  90048
Midwest Cancer Research Group, IncorporatedSkokie, Illinois  60077
MD Anderson Cancer Center at University of TexasHouston, Texas  77030-4009
Lynn Regional Cancer Center WestBoca Raton, Florida  33428
Wilshire Oncology Medical Group, Incorporated - La VerneLa Verne, California  91750
U.S. Oncology, IncorporatedHouston, Texas  77060